Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
The Journal of Experimental Medicine|July 17, 2013
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survivalChiara Gorrini, Pegah S Baniasadi, Isaac S Harris, et al.
Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.
JAMA|May 8, 2003
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto areaChristopher M Booth, Larissa M Matukas, George A Tomlinson, et al.
NPJ Breast Cancer|July 19, 2025
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapyJesús Fuentes-Antrás, Mitchell J Elliott, Sasha C Main, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Molecular Cancer Therapeutics|February 1, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast CancerSathyen A Prabhu, Omar Moussa, Christophe Gonçalves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast CancerMitchell J Elliott, Karen Howarth, Sasha Main, et al.
Cell Reports|October 26, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
Cell Reports|October 17, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
The Journal of Experimental Medicine|July 17, 2013
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survivalChiara Gorrini, Pegah S Baniasadi, Isaac S Harris, et al.
Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.
JAMA|May 8, 2003
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto areaChristopher M Booth, Larissa M Matukas, George A Tomlinson, et al.
NPJ Breast Cancer|July 19, 2025
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapyJesús Fuentes-Antrás, Mitchell J Elliott, Sasha C Main, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Nature Communications|March 14, 2024
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Molecular Cancer Therapeutics|February 1, 2023
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast CancerSathyen A Prabhu, Omar Moussa, Christophe Gonçalves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast CancerMitchell J Elliott, Karen Howarth, Sasha Main, et al.
Cell Reports|October 26, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
Cell Reports|October 17, 2023
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineagesHyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, et al.
Pageof 14